Back to browse

EXP001621

Paper

Ultrasound-dependent RNAi using TatU1A-rose bengal conjugate (2022)

Peptide

TatU1A-RB

Sequence: Fusion carrier: HIV-1 Tat CPP (core sequence YGRKKRRQRRR) fused to U1A RNA-binding protein; rose bengal (RB) conjugated (sonosensitizer). Exact full-length sequence not provided in paper.

RNA

shRNA

All experiment fields

Experiment Id EXP001621
Paper Ultrasound-dependent RNAi using TatU1A-rose bengal conjugate
Peptide TatU1A-RB
Delivery Success Class no
In Vivo Flag no
Uptake Confirmed yes
Label Confidence high
In Vitro Functional Effect yes
Endosomal Escape Evidence yes
Peptide Concentration 2 µM TatU1A-RB (cell treatment, 3 h incubation)
Rna Concentration 0.2 µM shGFP (cell treatment, 3 h incubation)
Mixing Ratio TatU1A-RB:shRNA = 10:1 molar (2 µM : 0.2 µM in cell treatment)
Formulation Format Protein/ RNA complex via U1A RNA-binding domain (endocytosis uptake; ultrasound-triggered escape)
Formulation Components TatU1A-RB + shRNA (U1A-binding sequence) in T buffer; no additional nanoparticles/excipients reported
Size Nm
Zeta Mv
Model Scope in_vitro
Model Type in vitro
Cell Lines Or Primary Cells CHO-EGFP (CHO cells stably expressing destabilized EGFP); CHO used for shRNA-Fam imaging
Animal Model
Administration Route
Output Type in vitro functional RNAi
Output Value EGFP fluorescence decreased to ~50% vs non-treated cells after ultrasound (US) with TatU1A-RB + shGFP; no significant knockdown without US
Output Units
Output Notes US-dependent cytosolic dispersion of shRNA-Fam observed (10–15 min US). RNAi requires shGFP and US; controls (US alone, TatU1A-RB alone, shControl) did not knock down. US: 1 MHz pulsed, duty cycle 30%, ~15 min (0.3 W/cm² in imaging; 0.3–0.5 W/cm² reported for knockdown/blood-cell experiments).
Toxicity Notes Not quantitatively reported in paper/SI; focus on delivery/knockdown. (No explicit cytotoxicity numbers provided.)
Curation Notes